Journal of Medical Economics
Volume 26, 2023 - Issue 1
Open access
1,432
Views
0
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan
Conor Chandlera Evidera Inc, Waltham, MA, United States of Americahttps://orcid.org/0000-0002-1365-9002View further author information
, Heather Burnettb Evidera Inc, St-Laurent, Canadahttps://orcid.org/0000-0003-1269-4276View further author information
, Kassandra Schaiblea Evidera Inc, Waltham, MA, United States of Americahttps://orcid.org/0000-0002-7822-3090View further author information
, Vishnu Senthila Evidera Inc, Waltham, MA, United States of Americahttps://orcid.org/0000-0001-6898-8826View further author information
, Masafumi Katoc Market Access, Public Affairs & Patient Experience, Takeda Pharmaceutical Company Ltd, Tokyo, Japanhttps://orcid.org/0000-0002-3813-1220View further author information
, Yuji Miurad Department of Medical Oncology, Toranomon Hospital, Tokyo, Japanhttps://orcid.org/0000-0002-7091-628XView further author information
, Takahiro Osawae Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japanhttps://orcid.org/0000-0003-4444-7958View further author information
, Hiroji Uemuraf Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-7943-1564View further author information
& https://orcid.org/0000-0001-7943-1564View further author information
Hiroyo Kuwabarac Market Access, Public Affairs & Patient Experience, Takeda Pharmaceutical Company Ltd, Tokyo, Japanhttps://orcid.org/0000-0001-6086-6453View further author information
show all
Pages 1009-1018
|
Received 27 Apr 2023, Accepted 26 Jul 2023, Published online: 12 Aug 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.